peposertib (M3814) / EMD Serono  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peposertib (M3814) / EMD Serono
MS100036_0020, NCT03770689 / 2018-002275-18: Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

Completed
2
19
Europe, US
Peposertib 50 mg, M3814, MSC2490484A, Peposertib 100 mg, Peposertib 150 mg, Peposertib 250 mg, Capecitabine, Radiotherapy (RT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Locally Advanced Rectal Cancer
06/21
02/22

Download Options